Home » Newsletters » BioWorld Science

BioWorld Science

Dec. 6, 1999

View Archived Issues

New cardioselective K(ATP) channel blocker inhibits ventricular fibrillation in ischemic rat model

Company Profile: Switch Biotech

Ciba Vision licenses Destiny's photodynamic therapy technology

Schering-Plough to manufacture Ampligen for HemispheRx

Alliance reports progress in phase III Oxygent trials

Pokeweed antiviral protein shows potential in AIDS

King Pharmaceuticals to acquire Medco

Abgenix enters human antibody drug collaboration with Human Genome Sciences

Pfizer presents novel hygromycin derivatives with antibacterial/antiprotozoal properties

p38 MAP kinase inhibitors described by Roche for inflammatory disorders

New series from Pfizer enhances serotonergic neurotransmission

Novel neuroprotective nitrate compound is the cornerstone of GoBang Therapeutics' pipeline

Hypoglycemics that enhance insulin sensitivity under study at SSP, presented at chemistry meeting

Novel anticonvulsants are associated with less toxicity

Cerebrus acquisition solidifies, enhances Vanguard Medica's R&D pipeline

Kyorin discusses design of anti-MRSA cephalosporins with affinity for PBP2'

MetaPhore awarded grants for research on metal-related therapeutics

Phase III Zomaril trial yields encouraging preliminary results

Promising treatment for Parkinson's disease in development at Juvantia

ImClone and Merck KGaA initiate first international phase III trial center of C225

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 19, 2026.
Precision psychiatry beyond, or before, biomarkers
BioWorld
There is broad agreement that psychiatric diagnoses in their current form are not reflective of any underlying biology, and that this is one of the things...
Keros reports beneficial effects of RKER-065 in ALS model
BioWorld Science
Keros Therapeutics Inc. has presented data regarding their activin receptor ligand trap, RKER-065, for the inhibition of the activin/myostatin signaling axis.
ADPD 2026: Can we prevent dementia? Scientists quantify it
BioWorld
Neurodegenerative disease and cognitive decline cannot be explained by a single process. Beta-amyloid plaques, hyperphosphorylated tau, alpha-synuclein, activated...
First-in-class POLG activator restores mtDNA across mutations
BioWorld Science
Researchers from Pretzel Therapeutics Inc. presented preclinical data of PX-578, a first-in-class POLG activator aimed at restoring mtDNA replication and...